Zimmer Biomet Holdings Inc Price, Chart & Factor Exposure
Free Data & Analytics AccessNext earnings: Wed, Feb 10, 2027, before the market opens · estimates and history
Zimmer Biomet Holdings Inc Forecast
Zimmer Biomet Holdings Inc short-term momentum is neutral (up over 2 of 4 look-backs: 5, 10, 20 and 30 trading days), a short-term NEUTRAL signal. The long-term trend is positive (6 of 8 checks up: price above, and slope of, its 50-, 100-, 150- and 200-day averages), a long-term BUY signal. Based on 20-day realised volatility of 28.1% a year, a typical one-standard-deviation range is 93.61–101.33 over a week, 89.57–105.37 over a month and 70.10–124.84 over a year. (Signals as of 1 Nov 2026.)
Zimmer Biomet Holdings Inc Price Chart
Zimmer Biomet Holdings Inc Factors
YoY +6.8%
YoY −4.8%
YoY +2.0%
YoY +6.6%
YoY −4.2%
YoY −1.3%
YoY −6.4%
YoY −3.9%
YoY +1.8%
YoY +4.2%
YoY +8.4%
YoY −39.7%
YoY −43.5%
YoY −11.4%
YoY −7.3%
YoY 0.0%
YoY −1.8%
Zimmer Biomet Holdings Inc fundamentals: income statement, balance sheet & cash flow
Zimmer Biomet Holdings Inc reported revenue of $8.23bn and net income of $705.2m in FY2025, the year ended 31 December 2025 — revenue up 7.2% and net income down 22.0% on the prior year. Free cash flow was $1.47bn. These figures are as reported in the filings, not restated: 28 fiscal years and 107 quarters of history, back to December 1998. 173 FINRA short-interest settlements are published alongside them, back to June 2019.
| USD millions | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | 31 Dec 2025 | 31 Dec 2024 | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 |
| Revenue | 8,231.5 | 7,678.6 | 7,394.2 | 6,939.9 | 6,827.3 |
| Cost of revenue | 3,159.6 | 2,191.2 | 2,083.8 | 2,019.5 | 1,960.4 |
| Gross profit | 5,071.9 | 5,487.4 | 5,310.4 | 4,920.4 | 4,866.9 |
| Research & development | 458.5 | 437.4 | 458.7 | 406.0 | 435.8 |
| Selling, general & admin. | 3,239.9 | — | — | — | — |
| Operating income | 1,362.2 | 1,285.7 | 1,277.7 | 696.3 | 860.3 |
| EBITDA | 2,217.4 | 2,250.9 | 2,220.2 | 1,494.7 | 1,645.1 |
| Interest expense | 292.8 | 218.0 | 201.2 | 164.8 | 208.4 |
| Pre-tax income | 830.8 | 1,036.6 | 1,067.3 | 403.5 | 499.0 |
| Income tax | 125.7 | 131.4 | 42.2 | 112.3 | 53.5 |
| Net income | 705.2 | 903.8 | 1,024.0 | 231.4 | 401.6 |
Download Zimmer Biomet Holdings Inc fundamentals
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_fundamentals&symbol=E.ZBH.NYSE&statement=all&freq=a&format=csv&years=10
Figures in USD, statements as filed and FINRA consolidated short interest. A cell is left blank where the filing does not report it or where the reported figure fails the statement’s own arithmetic. Short interest is the consolidated FINRA figure for the settlement date shown, published seven to eight business days later.
Research on Zimmer Biomet Holdings Inc
Explore MacroFinance macro & markets research and analysis.
Zimmer Biomet Holdings Inc Trading Strategies
58 backtested tactical asset allocation strategies hold SPY (US market) or XLV (Health Care sector), the closest tradable exposure to Zimmer Biomet Holdings Inc; 28 of them are invested now. Strategies currently invested are listed first.
| Strategy | Style | Rebalance | Now in SPY, XLV | CAGR | Sharpe | Max DD |
|---|---|---|---|---|---|---|
| Tactical Permanent Portfolio | Conservative | Monthly | Premium · upgrade to view | |||
| Zakamulin and Giner's Optimal Trend Following | Moderate | Monthly | Premium · upgrade to view | |||
| Movement Capital's Composite Strategy | Moderate | Monthly | Premium · upgrade to view | |||
| Harry Browne's Permanent Portfolio | Conservative | Monthly | 25% | 7.0% | 0.96 | -17.2% |
| Keller and Van Putten's Flexible Asset Allocation | Moderate | Monthly | Premium · upgrade to view | |||
| Ned Davis' Three Way Model | Moderate | Monthly | Premium · upgrade to view | |||
| 60_40 Benchmark | Moderate | Monthly | 60% | 8.2% | 0.93 | -29.5% |
| Dick Stoken's Active Combined Asset (ACA) - Monthly Trading | Moderate | Monthly | Premium · upgrade to view | |||
| PortfolioCharts' Golden Butterfly | Moderate | Monthly | 20% | 7.4% | 0.91 | -18.0% |
| US Cross-Asset Momentum | Moderate | Monthly | Premium · upgrade to view | |||
Hypothetical backtests over each ETF's own history; past performance does not guarantee future results. Upgrade to see every strategy's allocation and performance.
From creators
- P4 Demo Momentum by admin
- strategyx by admin
Statistical Distribution of Returns
PlusHow Zimmer Biomet Holdings Inc’s returns are distributed — and how they change in a given market regime.
Regime filters
| Market/Macro | Indicator | Criteria | Value | And (for Between) | Action |
|---|
No regime filter yet — the chart below shows every period. Add a factor condition, or pick a popular regime.
| Statistic | All periods | Matching |
|---|
About Zimmer Biomet Holdings Inc (United States)
Zimmer Biomet Holdings Inc is a listed security in the United States. This page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data (the last 10 years as CSV or JSON, no login).
Last updated: November 22, 2026
Frequently asked questions
What is Zimmer Biomet Holdings Inc?
What is the latest Zimmer Biomet Holdings Inc price?
Is Zimmer Biomet Holdings Inc in an uptrend?
How volatile is Zimmer Biomet Holdings Inc?
What factors affect Zimmer Biomet Holdings Inc?
Which trading strategies trade Zimmer Biomet Holdings Inc?
How are Zimmer Biomet Holdings Inc returns analysed?
Where can I download free Zimmer Biomet Holdings Inc historical data?
Free Zimmer Biomet Holdings Inc historical data (last 10 years)
Browse or instantly download the last 10 years of Zimmer Biomet Holdings Inc daily price history. A free account unlocks the full history, an Excel export with factors, and API access.
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_history&symbol=E.ZBH.NYSE&format=csv&years=10
| Date | Close |
|---|---|
| 2026-11-20 | 101.1 |
| 2026-11-19 | 101.47 |
| 2026-11-18 | 103.32 |
| 2026-11-17 | 102.09 |
| 2026-11-16 | 101.41 |
| 2026-11-13 | 103.21 |
| 2026-11-12 | 104.56 |
| 2026-11-11 | 107.47 |
| 2026-11-10 | 107.32 |
| 2026-11-09 | 108.33 |
About this stock
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, upper extremities, and trauma and CMFT products; sports medicine products for the repair of soft tissue injuries, used in the knee and shoulder; and craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open-heart surgery, trauma, or for deformities of the chest. It offers technology and data, bone cement, and surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, hospitals, healthcare institutions, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. It also offers ROSA Robot, which utilizes robotic technologies to assist a surgeon with implant positioning in total knee arthroplasty or partial knee arthroplasty; and the ZBEdge Platform connects robotic and digital technologies together to collect data before, during and after surgery, that can deliver insights to surgeons to assist in making informed decisions on patient care. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.
See how this market's returns behaved when a factor was in a given state, for example when Momentum was strong or bond yields were above 4%, and compare that with all periods.
Reading the chart
- Each bar is a return bucket; its height is the share of periods that landed there.
- All periods: every return in the date range.
- Matching periods: only the periods where all your filters were true. If orange shifts right of the grey, returns were better in that regime.
- Each period's return is the return over the following day, week or month (set by Timeframe), measured from the day the factor was read, so there is no look-ahead.
Adding a filter
- Factor: grouped the same way as the Factors section on this page (Quantitative, Country, Sector, …). Locked factors are listed but greyed out.
- Criteria: greater (>), greater or equal (≥), equal (=), smaller or equal (≤), smaller (<) or between two values.
- Value: depends on the factor.
- Momentum and Trend are signals from −1 to +1, picked as −100 to +100 in steps of 25.
- Mean Reversion is a z-score of price against its 250-day mean, picked in σ from −3 to +3.
- Everything else is a number you type. The line under the box shows the latest reading and its typical range over the last 10 years.
Add several filters to combine conditions; a period must pass every one. Narrow the window with the From/To dates or the 1Y / 5Y / 10Y / MAX buttons; Clear resets filters and dates.
Return statistics
- Unfiltered vs Filtered: all periods vs matching periods.
- Average return, Std dev and Sharpe are annualised (252 days, 52 weeks, 12 months, 6 two-month periods, 4 quarters).
- Maximum drawdown compounds non-overlapping periods; in the Filtered column it assumes you held only while the condition was true.
- Min, 25th percentile, median, 75th percentile and max are per period, not annualised.